IBEX Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

IBEX Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-73	Closed	-$13K	–	266
2016 Q4	$13K	Buy	+73	New	+$14.8K	0.01%	265

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

IBEX Wealth Advisors's NKTR Position: Q1 2017 in Review

IBEX Wealth Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2017, closing a stake of 73 shares — an estimated $13K sold.

IBEX Wealth Advisors first reported a position in NKTR in Q4 2016 and held it in 1 quarter. The position peaked at $13K in Q4 2016. 201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

IBEX Wealth Advisors reported no remaining Nektar Therapeutics position as of Q1 2017 after selling out during the quarter.
IBEX Wealth Advisors sold 73 Nektar Therapeutics shares in Q1 2017, an estimated $13K.
IBEX Wealth Advisors first reported a position in Nektar Therapeutics in Q4 2016 and held it in 1 quarter.
IBEX Wealth Advisors's Nektar Therapeutics position peaked at $13K in Q4 2016.
201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on IBEX Wealth Advisors's 13F filing for Q1 2017, filed 25 May 2017.